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To the Editor: Tropheryma 
whipplei causes Whipple disease, 
a rare multisystemic disorder that 
affects mainly middle-aged white 
men and is most widely distributedin 
Europe and North America (1). In 
the general population of France, T. 
whipplei DNA was found in 2%–4% 
of stool samples and T. whipplei–
specific antibodies were found in 
51% of serum samples (2). Still, the 
prevalence of classic Whipple disease, 
which causes arthralgia, diarrhea, and 
weight loss, remains extremely low 
(1). Whipple disease has 4 known 
manifestations: 1) classic Whipple 
disease; 2) focused chronic infections, 
mainly endocarditis; 3) acute 
infections, such as gastroenteritis, 
bacteremia, and pneumonia; and 4) 
asymptomatic T. whipplei carriage in 
healthy persons (1–5). T. whipplei is 
thought to be transmitted through oral 
and oro–fecal routes by human-to-
human contact (2,6).
The pathogen was cultivated in 
2000, and 2 genomes were sequenced 
(reference strains Twist and TW08/27) 
(7,8). These events made possible a 
genotyping system based on 4 highly 
variable genetic sequences found by 
genome comparison (TW133, ProS, 
SecA, Pro184) (9). Since 2007, we 
have applied this system to patient 
samples positive for T. whipplei from 
central Europe and sub-Saharan Africa 
(2,3,9,10). The system showed a higher 
discriminatory power than previous 
typing methods and improved the 
genotyping resolution of T. whipplei, 
promoting better understanding of 
its epidemiology on the molecular 
level (9).
Since 2003, we have subcultured 
strain Twist every 3 weeks. In 2007 
and 2012, we compared sequences 
for the subcultured strains with that 
for the 2003 strain. We found that 
the spacer sequence remained stable 
over the ≈10-year period. This finding 
suggests a high intrastrain genetic 
stability and highlights the value of the 
typing system, which is stable. Thus, a 
change in genotype in a patient with 
Whipple disease must be interpreted 
as an infection with a different strain 
and cannot be attributed to mutation of 
the original strain.
To date, 191 samples positive for 
T. whipplei collected from patients 
from central Europe (France, Germany, 
Switzerland, Austria, and Italy) 
have been typed, revealing a genetic 
diversity by identifying 72 different 
T. whipplei genotypes: 1–23, 25–45, 
58–60, 76–77, 82–102, and 111–
116. The discriminatory power was 
high (Hunter-Gaston discriminatory 
index 0.9298) for all samples from 
Europe. No connection between 
clinical manifestations and T. whipplei 
genotypes has been described. Reasons 
might be found either in an unknown 
link between genomics in T. whipplei 
and clinical outcome or might be 
because the typing system cannot 
identify possible virulence factors. 
Genotypes 1 and 3 are predominant 
(1,3), accounting for 35.1% of all tested 
T. whipplei samples from Europe.
Genotype 3 is the most common 
T. whipplei genotype in Europe (19.9% 
of all samples) and could be considered 
epidemic in and specific to France, 
Switzerland, and Italy. This genotype 
was proposed to be responsible for 
small outbreaks caused by clonal 
strains, such as gastroenteritis among 
young children or the strain carried by 
homeless persons in Marseille, France 
(3,6), but it has not been described in 
Germany or Austria (Figure). 
Genotype 1 is found throughout 
central Europe and is the second 
most common genotype (15.2% of 
all samples) (Figure). Predominance 
of this genotype in Germany is high 
(46.2%, n = 13) and Austria (80%, n = 
5). Infection with this genotype seems 
to be endemic in the population of 
the area, although no outbreaks have 
been reported. 
Of 191samples, a total of 55 
(28.8%) showed a unique genotype 
consistent with the high genetic 
variability in T. whipplei specimens. 
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of these singletons showed no 
correlation between clusters and 
geographic origin of samples.
Of the 191 samples, a total of 
66 (34.6%) were from Marseille and 
represented 40 different genotypes. 
This finding underscores the broad 
heterogeneity in T. whipplei. Twelve 
(18.5%) of the 66 tested samples were 
genotype 3, which might be linked to 
the local outbreak among homeless 
persons mentioned above. Genotype 
1, which is endemic to France, was 
found in only 2 (3.1%) persons in 
Marseille. The fact that Marseille 
is a metropolitan area with a high 
migration rate could play a role in the 
vast diversity of T. whipplei genotypes 
found there
Questions regarding the epi-
demiologic character of Whipple 
disease remain unanswered, such as 
why the bacterium is highly prevalent 
but the disease is not. Persons with 
the putative immunological defect 
probably responsible for classic 
Whipple disease (1) have the highest 
bacterial load in their stools. But these 
persons are unlikely to come into 
direct contact with one another. Thus, 
propagation of this bacterium on a 
large scale might be relatively limited, 
which could explain the high genetic 
diversity in the bacterial specimens 
assessed so far.
Two predominant genotypes 
seem to break out of this pattern: 
genotypes 1 and 3. Genotype 3 could 
be considered a genotype that causes 
small epidemics, whereas genotype 
1 could be considered a genotype 
endemic to central Europe. Reasons 
for the success of these 2 genotypes 
remain unknown, but improvement 
of genotyping methods could provide 
the answers.
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To the Editor: Yersinia pestis 
causes plague, which primarily affects 
rodents, but is an invasive and virulent 
pathogen among humans. Y. pestis 
infection is endemic in small rodent 
populations in different parts of the 
world, and the bacterium is considered 
a potential bioweapon because it can 
be easily isolated, produced, dried, and 
dispersed as an aerosol. Antimicrobial 
drug treatment can be lifesaving during 
the early stages of illness; hence, 
rapid and sensitive methods for Y. 
pestis detection in environmental and 
clinical samples are required. Multiple 
PCR assays for Y. pestis detection that 
primarily detect markers located on 
plasmids have been developed (1–6). 
The plasminogen activator/coagulase 
(pla) gene, located on plasmid pPCP1, 
is incorporated into most Y. pestis 
PCR assays, and in several studies it 
was the prime or sole marker (1,2,5,7–
9). Reasons for including pla in these 
assays are its occurrence in multiple 
copies, its absence from closely 
related Yersinia species, and its role in 
Y. pestis virulence (1,4,5).
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